Save the Children, drug company GSK in new partnership
13 May, 2013 - The British multinational pharmaceutical giant GlaxoSmithKline (GSK)
is giving Save the Children $23 million and entering into a five-year partnership
with the charity to try to save the lives of 1 million children. The chief executives
of the two groups visited a remote health clinic in Kenya on Thursday where they spoke
to a mother who was devastated to see her three children die of diarrhea, but was
happy that her 5-year-old daughter was getting treatment for pneumonia. ``That story
is the story globally. We see far too many children dying from diarrhea, but we've
also turned a corner,'' said GSK chief executive Andrew Witty. Justin Forsyth,
the head of Save the Children said GSK, one of the world's leading drug makers, has
been working to increase expanded access to medicine over the last five to six years,
an approach he said has high shareholder support. One initiative in the new partnership
is to transform an antiseptic used in mouthwash into a lifesaving product to prevent
infections when umbilical cords are cut. Another is an accelerated rollout of a child-friendly
antibiotic used to treat pneumonia. ``We need to make sure we are making available
to the best of our availability our strengths and talents not only for folks who live
in rich countries but wherever there are needs,'' Witty said. Forsyth said he used
to campaign against GSK when ``they kept the prices very high for AIDS drugs.'' But
he said GSK has changed and is now at the forefront in terms of access to medicine
and investment in malaria vaccines. Save the Children will also have a seat on a
GSK research and development board for pediatric medicine. (Source: AP)